Literature DB >> 1554834

Bacteremia due to Achromobacter xylosoxidans in patients with cancer.

C Legrand1, E Anaissie.   

Abstract

Bacteremia due to Achromobacter xylosoxidans is rare, and little information on treatment is available. Between 1983 and 1988, A. xylosoxidans was recovered from 26 cultures of blood from 10 patients with cancer and clinical signs of infection, including one patient with septic shock and two with pneumonia. Neutropenia did not seem to be a predisposing factor. The infection may have been catheter related in four patients and associated with gastrointestinal pathology in four others. Probable cause was not determined in the remaining two. In vitro studies of susceptibility showed that the isolates were susceptible to trimethoprim-sulfamethoxazole (TMP-SMZ), the antipseudomonal penicillins, ceftazidime, cefoperazone, and imipenem; moderately susceptible to ciprofloxacin; and resistant to ceftriaxone, cefotaxime, cefoxitin, ceftizoxime, aztreonam, and amikacin. All patients receiving therapy recovered, including those six who received TMP-SMZ or a beta-lactam antibiotic as a single agent. A. xylosoxidans bacteremia is a significant infection and may be catheter related or associated with gastrointestinal pathology. The infection usually responds to therapy with TMP-SMZ or an appropriate beta-lactam antibiotic.

Entities:  

Mesh:

Year:  1992        PMID: 1554834     DOI: 10.1093/clinids/14.2.479

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  21 in total

1.  Meningitis caused by Alcaligenes (Achromobacter) xylosoxidans associated with epidural catheter.

Authors:  J M Ramos; R Fernández-Roblas; P García-Ruiz; F Soriano
Journal:  Infection       Date:  1995 Nov-Dec       Impact factor: 3.553

2.  Bacteremia due to glucose non-fermenting gram-negative bacilli in patients with hematological neoplasias and solid tumors.

Authors:  R Martino; C Martínez; R Pericas; R Salazar; C Solá; S Brunet; A Sureda; A Domingo-Albós
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-07       Impact factor: 3.267

3.  Investigation of hospital-acquired infections due to Alcaligenes denitrificans subsp. xylosoxydans by DNA restriction fragment length polymorphism.

Authors:  M Cheron; E Abachin; E Guerot; M el-Bez; M Simonet
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

4.  Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis.

Authors:  J W Krzewinski; C D Nguyen; J M Foster; J L Burns
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

Review 5.  Bacteremia and respiratory involvement by Alcaligenes xylosoxidans in patients infected with the human immunodeficiency virus.

Authors:  R Manfredi; A Nanetti; M Ferri; F Chiodo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-12       Impact factor: 3.267

6.  Ribosomal DNA-directed PCR for identification of Achromobacter (Alcaligenes) xylosoxidans recovered from sputum samples from cystic fibrosis patients.

Authors:  Lixia Liu; Tom Coenye; Jane L Burns; Paul W Whitby; Terrence L Stull; John J LiPuma
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

7.  Pulmonary Infection Caused by Achromobacter xylosoxidans in a Patient with Carcinoma of Epiglottis: A Rare Case.

Authors:  Priyamvada Roy
Journal:  J Clin Diagn Res       Date:  2014-05-15

8.  Achromobacter xylosoxidans bacteremia: a 10-year analysis of 54 cases.

Authors:  J Gómez-Cerezo; I Suárez; J J Ríos; P Peña; M J García de Miguel; M de José; O Monteagudo; P Linares; A Barbado-Cano; J J Vázquez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-05-16       Impact factor: 3.267

9.  Epidemiological typing of clinical isolates of Achromobacter xylosoxidans: comparison of phenotypic and genotypic methods.

Authors:  M Kaur; P Ray; M Bhatty; M Sharma
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-04-17       Impact factor: 3.267

Review 10.  Achromobacter Infections and Treatment Options.

Authors:  Burcu Isler; Timothy J Kidd; Adam G Stewart; Patrick Harris; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.